Share tips: Health stock gains competitive edge

A newer and lighter version of this health firm's best-selling eye-scanner could be a game-changer in this $2bn market, says Paul Hill.

Opthalmologists can tell a great deal about someone's overall health just by looking into their eyes. From retinal detachments, cataracts and glaucomas to diseases such as cancer and diabetes, many serious conditions can be detected early on via eye exams. The major benefit is that these are cheap and non-invasive compared to many procedures.

Optos was set up in 1992 after founder Douglas Anderson's five-year-old son became blind in one eye. The firm is now the global leader in retinal diagnostics: more than 4,500 of its scanning machines are installed worldwide the majority in America. These instruments take wide-angle, high-resolution digital images (optomaps') of 82% of the retina. No other device can do this in a single picture. The devices are backed by a raft of clinical data, giving Optos a major competitive edge in this $2bn-$3bn market.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Explore More

Paul gained a degree in electrical engineering and went on to qualify as a chartered management accountant. He has extensive corporate finance and investment experience and is a member of the Securities Institute.

Over the past 16 years Paul has held top-level financial management and M&A roles for blue-chip companies such as O2, GKN and Unilever. He is now director of his own capital investment and consultancy firm, PMH Capital Limited.

Paul is an expert at analysing companies in new, fast-growing markets, and is an extremely shrewd stock-picker.